EUROAPI and Priothera Enter CDMO Collaboration to Advance Oncology Project

Paris – June 18, 2024 – EUROAPI has announced a 5-year development and manufacturing agreement with Priothera, a biotechnology firm focused on hematological malignancies and CAR-T cell treatments. Priothera, based in Dublin, Ireland, also operates a subsidiary in Saint-Louis, France.

Under this collaboration, EUROAPI will handle the development and industrialization of mocravimod, an innovative molecule for blood cancer treatment. This project will be conducted at EUROAPI’s Budapest site, an expert center for complex chemistry.

Mocravimod, a S1P1 receptor modulator, aims to reduce relapses and increase survival rates in blood cancer patients. It is currently in a global phase 3 trial involving 250 Acute Myeloid Leukemia patients across multiple regions, including the US, Europe, Asia, and Latin America. Both the EMA and US FDA have granted it Orphan Drug designation.

This agreement signifies EUROAPI's capability to meet the increasing demand for advanced oncology treatments, aligning with the expected rise in global cancer medicine spending to $375 billion by 2027.